MedTrace Logo

Impact of Catch-up HPV Vaccination

NCT05462249 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 354

Last updated 2025-04-30

No results posted yet for this study

Summary

Each year in France, more than 6000 new cases of HPV inducted cancers are recorded. The vaccinal cover stays insufficient since less than 30% of the french population is vaccinated. Therefore french studies about vaccine efficacy and especially about the catch-up vaccine (done after 15years old) are needed.

HPVAC2 is a prospective, analytic and monocentric study designed to learn the impact of the catch-up HPV vaccination.

Women from 25 years old and born after 1984 may be included if they come to the Brest CHU to do their regular cervical smear. At this time, a survey will be given to know their vaccinal status.

The aim of the study is to prove the efficacy of the catch up vaccination by analyzing the cervical smears results and by comparing the vaccinated group with the not-vaccinated group.

Conditions

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Philippe MERVIEL, PU-PH · Head of the gynecologic department in Brest Hospital

Eligibility

Min Age
25 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462249 on ClinicalTrials.gov